CONCURRENT CHEMORADIOTHERAPY WITH HELICAL TOMOTHERAPY FOR OROPHARYNGEAL CANCER: A PRELIMINARY RESULT

文化大學機構典藏 CCUR > 體育運動健康學院 > 運動教練研究所 > 期刊論文 > Item 987654321/20951

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/20951

题名:	CONCURRENT CHEMORADIOTHERAPY WITH HELICAL TOMOTHERAPY FOR OROPHARYNGEAL CANCER: A PRELIMINARY RESULT
作者:	Shueng, PW (Shueng, Pei-Wei) Wu, LJ (Wu, Le-Jung) Chen, SY (Chen, Shiou-Yi) Hsiao, CH (Hsiao, Chi-Huang) Tien, HJ (Tien, Hui-Ju) Cheng, PW (Cheng, Po-Wen) Kuo, YS (Kuo, Ying-Shiung) Chen, YJ (Chen, Yu-Jen) Chen, CA (Chen, Chien-An) Hsieh, PY (Hsieh, Pei-Ying) Hsieh, CH (Hsieh, Chen-Hsi)
贡献者:	運教所
关键词:	Concurrent chemoradiation Helical tomotherapy Intensity-modulated radiotherapy Oropharyngeal cancer
日期:	2010-07
上传时间:	2011-12-09 14:57:48 (UTC+8)
摘要:	Purpose: To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. Methods and Materials: Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70Gy, 63Gy, and 56Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30mg/m(2), plus 5-fluorouracil (425mg/m(2))/leucovorin (30mg/m(2)) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose volume histograms. Results: The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted. Conclusion: Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings. (C) 2010 Elsevier Inc.
显示于类别:	[運動教練研究所] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	729	检视/开启

在CCUR中所有的数据项都受到原著作权保护.

数据加载中.....